JP2018508516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508516A5 JP2018508516A5 JP2017546075A JP2017546075A JP2018508516A5 JP 2018508516 A5 JP2018508516 A5 JP 2018508516A5 JP 2017546075 A JP2017546075 A JP 2017546075A JP 2017546075 A JP2017546075 A JP 2017546075A JP 2018508516 A5 JP2018508516 A5 JP 2018508516A5
- Authority
- JP
- Japan
- Prior art keywords
- eribulin
- breast cancer
- medicament
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128373P | 2015-03-04 | 2015-03-04 | |
| US62/128,373 | 2015-03-04 | ||
| US201562264068P | 2015-12-07 | 2015-12-07 | |
| US62/264,068 | 2015-12-07 | ||
| PCT/US2016/020734 WO2016141209A1 (en) | 2015-03-04 | 2016-03-03 | Combination of a pd-1 antagonist and eribulin for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508516A JP2018508516A (ja) | 2018-03-29 |
| JP2018508516A5 true JP2018508516A5 (https=) | 2019-04-18 |
| JP6951248B2 JP6951248B2 (ja) | 2021-10-20 |
Family
ID=55586425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546075A Active JP6951248B2 (ja) | 2015-03-04 | 2016-03-03 | がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10945990B2 (https=) |
| EP (1) | EP3265122B1 (https=) |
| JP (1) | JP6951248B2 (https=) |
| KR (1) | KR20170122810A (https=) |
| CN (1) | CN107810013B (https=) |
| AU (1) | AU2016226157B2 (https=) |
| BR (1) | BR112017018872A2 (https=) |
| CA (1) | CA2978311A1 (https=) |
| IL (1) | IL254133B (https=) |
| MX (1) | MX386547B (https=) |
| RU (1) | RU2737216C2 (https=) |
| SG (1) | SG11201706872SA (https=) |
| WO (1) | WO2016141209A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2522663T1 (sl) | 2004-06-03 | 2015-08-31 | Eisai R&D Management Co., Ltd. | Vmesne spojine za pripravo halihondrina B |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN102369008B (zh) | 2009-03-30 | 2014-10-29 | 卫材R&D管理有限公司 | 脂质体组合物 |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| AU2016226157B2 (en) | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| NZ738406A (en) * | 2015-06-11 | 2023-04-28 | Bionomics Ltd | Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| WO2018071792A1 (en) * | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| US20190270802A1 (en) * | 2016-10-21 | 2019-09-05 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist |
| US20200129473A1 (en) * | 2017-07-21 | 2020-04-30 | Eisai R&D Management Co., Ltd. | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| AU2019285640A1 (en) * | 2018-06-15 | 2021-01-21 | Board Of Regents Of The University Of Texas System | Methods of treating and preventing breast cancer with S-equol |
| JP2021535187A (ja) | 2018-06-15 | 2021-12-16 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | Ｓ−エクオールを用いた黒色腫の処置及び予防方法 |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| JP2022553421A (ja) * | 2019-10-28 | 2022-12-22 | エンジーケム ライフサイエンシーズ コーポレーション | がんの処置のための方法および組成物 |
| WO2025049528A1 (en) * | 2023-08-29 | 2025-03-06 | Cullinan Amber Corp. | Combination therapies for cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP4454151B2 (ja) | 1998-06-17 | 2010-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 大環状類似体及びそれらの使用並びに調製方法 |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| SI2522663T1 (sl) | 2004-06-03 | 2015-08-31 | Eisai R&D Management Co., Ltd. | Vmesne spojine za pripravo halihondrina B |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| BRPI0817909B1 (pt) | 2007-10-03 | 2022-06-21 | Eisai R&D Management Co., Ltd | Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| RU2579511C2 (ru) | 2010-01-26 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производные фуро[3,2-в]пирана, применимые в синтезе аналогов |
| JP2014508165A (ja) | 2011-03-02 | 2014-04-03 | モルフォテック、インク． | 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与 |
| EP2686441B1 (en) * | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014159562A1 (en) * | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
| ES2822665T3 (es) * | 2013-05-31 | 2021-05-04 | Merck Sharp & Dohme | Terapias de combinación para el cáncer |
| CA2912346A1 (en) | 2013-06-11 | 2014-12-18 | Novartis Ag | Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent |
| BR112015029386B1 (pt) * | 2013-06-26 | 2023-11-14 | Eisai R&D Management Co., Ltd. | Uso de eribulina e lenvatinibe como terapia de combinação e kit |
| US9457019B2 (en) * | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| KR20240144452A (ko) * | 2014-03-05 | 2024-10-02 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료 |
| US20170100367A1 (en) | 2014-05-28 | 2017-04-13 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
| AU2016226157B2 (en) | 2015-03-04 | 2022-01-27 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and eribulin for treating cancer |
-
2016
- 2016-03-03 AU AU2016226157A patent/AU2016226157B2/en not_active Ceased
- 2016-03-03 BR BR112017018872A patent/BR112017018872A2/pt not_active IP Right Cessation
- 2016-03-03 RU RU2017132877A patent/RU2737216C2/ru active
- 2016-03-03 WO PCT/US2016/020734 patent/WO2016141209A1/en not_active Ceased
- 2016-03-03 EP EP16710891.9A patent/EP3265122B1/en not_active Revoked
- 2016-03-03 US US15/554,540 patent/US10945990B2/en active Active
- 2016-03-03 CN CN201680025588.3A patent/CN107810013B/zh not_active Expired - Fee Related
- 2016-03-03 KR KR1020177027617A patent/KR20170122810A/ko not_active Ceased
- 2016-03-03 SG SG11201706872SA patent/SG11201706872SA/en unknown
- 2016-03-03 JP JP2017546075A patent/JP6951248B2/ja active Active
- 2016-03-03 MX MX2017011206A patent/MX386547B/es unknown
- 2016-03-03 CA CA2978311A patent/CA2978311A1/en not_active Abandoned
-
2017
- 2017-08-24 IL IL254133A patent/IL254133B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508516A5 (https=) | ||
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2018512391A5 (https=) | ||
| EP4096671B1 (en) | Combination therapy for treating abnormal cell growth | |
| JP7578643B2 (ja) | 異常な細胞成長を処置するための方法および組成物 | |
| JP2019530706A5 (https=) | ||
| JP6787792B2 (ja) | がんの処置のための併用治療 | |
| JP2019536805A5 (https=) | ||
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2017506227A5 (https=) | ||
| ES3036485T3 (en) | Combination comprising everolimus and amcenestrant | |
| ES2922378T3 (es) | C. novyi para el tratamiento de tumores sólidos en seres humanos | |
| JP2014511383A5 (https=) | ||
| JP2016530280A5 (https=) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| KR20190025733A (ko) | 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물 | |
| JP2019508476A5 (https=) | ||
| RU2020122083A (ru) | Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины | |
| AU2023336057A1 (en) | Dosage regimens of estrogen receptor degraders | |
| JP2021505669A5 (https=) | ||
| JP2019501957A5 (https=) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2023550740A5 (https=) | ||
| CN110545803A (zh) | 用于淋巴结阳性、早期、激素受体阳性、人表皮生长因子受体2阴性乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合 | |
| JP2018522881A5 (https=) |